A. A. Gurkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. A. Gurkina has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Nikolai Igorevich Stuklov
RUDN University, 6 Miklukho-Maklaya ul., Moscow, Russian Federation, 117198
7 shared publications - Rinat R. Gimadiev
People’s Friendship University of Russia (RUDN University)
5 shared publications - M. S. Kovalchuk
Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN university), the Ministry of Education and Science of Russia
3 shared publications - N. D. Kisliy
Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)
3 shared publications - N. V. Varekha
Рeoples’ Friendship University of Russia named after Patrice Lumumba
3 shared publications - Valentin A. Kokorin
Department of Hospital Therapy with Courses in Endocrinology, Hematology and Clinical Laboratory Diagnostics, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow 117198, Russia
2 shared publications
Latest Publications
- 8 June 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (2) , 129-136
Comparative analysis of the effectiveness of iron therapy with a hepcidin-independent absorption mechanism in patients with chronic heart failure
The aim of this study is to describe anemia in chronic heart failure (CHF) and to evaluate the effectiveness of oral therapy with sucrosomial iron (SiderAL® Forte) in this group. Material and methods. The study included 56 patients with CHF and anemia. Results. Anemia in CHF corresponds to anemia of chronic disease (ACD) with the development of iron deficiency (ID) in 75% of patients. The use of sucrosomial iron leads to a significant increase in hemoglobin and serum ferritin levels, a decrease in the concentration of N-terminal pro-brain natriuretic peptide, an improvement in exercise tolerance, a reduction in the functional class of CHF, and a decrease in mortality over a 2-year follow-up period. Conclusion. The addition of iron preparations with hepcidin-independent absorption to standard CHF therapy shows a significant positive effect across all criteria and can be recommended for this category of patients in routine clinical practice.
- 8 June 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (2) , 129-136
Comparative analysis of the effectiveness of iron therapy with a hepcidin-independent absorption mechanism in patients with chronic heart failure
The aim of this study is to describe anemia in chronic heart failure (CHF) and to evaluate the effectiveness of oral therapy with sucrosomial iron (SiderAL® Forte) in this group. Material and methods. The study included 56 patients with CHF and anemia. Results. Anemia in CHF corresponds to anemia of chronic disease (ACD) with the development of iron deficiency (ID) in 75% of patients. The use of sucrosomial iron leads to a significant increase in hemoglobin and serum ferritin levels, a decrease in the concentration of N-terminal pro-brain natriuretic peptide, an improvement in exercise tolerance, a reduction in the functional class of CHF, and a decrease in mortality over a 2-year follow-up period. Conclusion. The addition of iron preparations with hepcidin-independent absorption to standard CHF therapy shows a significant positive effect across all criteria and can be recommended for this category of patients in routine clinical practice.
- Open Access
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 171-181
Development of a method for differential diagnosis of iron deficiency anemia and anemia of chronic disease based on demographic data and routine laboratory tests using machine learning technologies
Background. The study of machine learning methods, a branch of artificial intelligence science, is relevant for the development of optimal screening strategies, identification of risk groups, and application of less expensive and more accessible laboratory tests to assess the body iron status. Aim. To select an appropriate artificial intelligence algorithm for predicting serum ferritin (SF) levels and to evaluate its applicability for differential diagnosis of iron deficiency anemia and anemia of chronic diseases. Materials and methods. A dataset of 9771 patients with micro‑normocytic anemia was used to create the model. On the basis of demographic data (gender and age), clinical blood count, C‑reactive protein level and known SF level, a regression model was developed to calculate the expected SF concentration in a particular patient and, using the same parameters, a classification model to determine the SF level group to which the patient belongs: I – 15 μg / L; II – 15–100 μg / L; III – 100–300 μg / L; Iv – ≥ 300 μg / L. Results. As a result, the regression model has moderate predictive ability (R2 = 0.70; median absolute error was 10.7 μg / L), the correlation coefficient between known and predicted SF level was r = 0.854 (p 0.05). The obtained classification model has high diagnostic accuracy for different clinical groups according to the SF level (AuC ROC was 0.91; 0.79; 0.84; 0.90 and 0.96; 0.76; 0.71; 0.82 for patients with reduced hemoglobin levels in women ( 120 g / L) and men ( 130 g / L) in groups I, II, III, Iv, respectively). Conclusion. Prediction of SF level using the developed models can be used as an accurate and clinically relevant tool for differential diagnosis of iron deficiency anemia (predicted SF is decreased ( 100 μg / L), C‑reactive protein is normal) and anemia of chronic diseases (predicted SF is normal or increased (100 μg / L), C‑reactive protein is increased) in real medical practice.
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 171-181
Open AccessDevelopment of a method for differential diagnosis of iron deficiency anemia and anemia of chronic disease based on demographic data and routine laboratory tests using machine learning technologies
Background. The study of machine learning methods, a branch of artificial intelligence science, is relevant for the development of optimal screening strategies, identification of risk groups, and application of less expensive and more accessible laboratory tests to assess the body iron status. Aim. To select an appropriate artificial intelligence algorithm for predicting serum ferritin (SF) levels and to evaluate its applicability for differential diagnosis of iron deficiency anemia and anemia of chronic diseases. Materials and methods. A dataset of 9771 patients with micro‑normocytic anemia was used to create the model. On the basis of demographic data (gender and age), clinical blood count, C‑reactive protein level and known SF level, a regression model was developed to calculate the expected SF concentration in a particular patient and, using the same parameters, a classification model to determine the SF level group to which the patient belongs: I – 15 μg / L; II – 15–100 μg / L; III – 100–300 μg / L; Iv – ≥ 300 μg / L. Results. As a result, the regression model has moderate predictive ability (R2 = 0.70; median absolute error was 10.7 μg / L), the correlation coefficient between known and predicted SF level was r = 0.854 (p 0.05). The obtained classification model has high diagnostic accuracy for different clinical groups according to the SF level (AuC ROC was 0.91; 0.79; 0.84; 0.90 and 0.96; 0.76; 0.71; 0.82 for patients with reduced hemoglobin levels in women ( 120 g / L) and men ( 130 g / L) in groups I, II, III, Iv, respectively). Conclusion. Prediction of SF level using the developed models can be used as an accurate and clinically relevant tool for differential diagnosis of iron deficiency anemia (predicted SF is decreased ( 100 μg / L), C‑reactive protein is normal) and anemia of chronic diseases (predicted SF is normal or increased (100 μg / L), C‑reactive protein is increased) in real medical practice.
- Open Access
- 3 March 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (1) , 33-38
Correction of anemia using an iron supplement with a hepcidin-independent absorption mechanism in patients with chronic heart failure with preserved left ventricular ejection fraction
Aim. To characterize anaemia in chronic heart failure (CHF) with preserved left ventricular ejection fraction (CHFpEF) and evaluate the effectiveness of an iron supplement with a hepcidin- independent absorption mechanism. Material and methods. An uncontrolled study included 30 patients with CHFpEF NYHA class I-III and anaemia. Patients received "standard therapy" for CHF in combination with sucrosomial iron (60 mg/day orally) for three months. Treatment response was assessed via clinical blood test, iron metabolism parameters, inflammatory markers, and functional tests at baseline and three months post-treatment. Results. Anaemia in CHFpEF corresponds to anaemia of chronic disease with elevated hepcidin content, 219 (149-553) ng/mL occurs with impaired absorption and metabolism of iron and the development of iron deficiency. Hemoglobin levelincreased from 115 (98-117) g/L to 120 (103-133) g/L, p = 0.01, red blood cell count increased from 3.6 (3.5-4.1) × 1012/L to 4 (3.7-5.3) × 1012/L, p = 0.05, and serum ferritin increased from 106 (40-181) μg/L to 117 (83-166) μg/L, p = 0.04. N-terminal natriuretic propeptide (NT-proBNP) level decreased from 374 (330-443) ng/mL to 236 (128-349) ng/mL, p = 0.004. After treatment, exercise tolerance exercise tolerance improved: 6-minute walk test distance increased from 343.1 ± 100 m to 397±73 m (p = 0.01). Quality of life (QoL) level increased and was determined by the clinical status assessment scale (CAS), p = 0.01 and by the Minnesota Health Failure Questionnaire (MHFLQ), p = 0.002. Conclusion. Adding oral hepcidin- independent iron to standard HFpEF therapy in patients with CHFpEF and anaemia significantly increased hemoglobin and serum ferritin levels, exercise tolerance, and QoL scores while reducing NT-proBNP levels and NYHA functional class after three months.
- 3 March 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (1) , 33-38
Open AccessCorrection of anemia using an iron supplement with a hepcidin-independent absorption mechanism in patients with chronic heart failure with preserved left ventricular ejection fraction
Aim. To characterize anaemia in chronic heart failure (CHF) with preserved left ventricular ejection fraction (CHFpEF) and evaluate the effectiveness of an iron supplement with a hepcidin- independent absorption mechanism. Material and methods. An uncontrolled study included 30 patients with CHFpEF NYHA class I-III and anaemia. Patients received "standard therapy" for CHF in combination with sucrosomial iron (60 mg/day orally) for three months. Treatment response was assessed via clinical blood test, iron metabolism parameters, inflammatory markers, and functional tests at baseline and three months post-treatment. Results. Anaemia in CHFpEF corresponds to anaemia of chronic disease with elevated hepcidin content, 219 (149-553) ng/mL occurs with impaired absorption and metabolism of iron and the development of iron deficiency. Hemoglobin levelincreased from 115 (98-117) g/L to 120 (103-133) g/L, p = 0.01, red blood cell count increased from 3.6 (3.5-4.1) × 1012/L to 4 (3.7-5.3) × 1012/L, p = 0.05, and serum ferritin increased from 106 (40-181) μg/L to 117 (83-166) μg/L, p = 0.04. N-terminal natriuretic propeptide (NT-proBNP) level decreased from 374 (330-443) ng/mL to 236 (128-349) ng/mL, p = 0.004. After treatment, exercise tolerance exercise tolerance improved: 6-minute walk test distance increased from 343.1 ± 100 m to 397±73 m (p = 0.01). Quality of life (QoL) level increased and was determined by the clinical status assessment scale (CAS), p = 0.01 and by the Minnesota Health Failure Questionnaire (MHFLQ), p = 0.002. Conclusion. Adding oral hepcidin- independent iron to standard HFpEF therapy in patients with CHFpEF and anaemia significantly increased hemoglobin and serum ferritin levels, exercise tolerance, and QoL scores while reducing NT-proBNP levels and NYHA functional class after three months.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 12 (3)
The "Ferritin 2023" program to study population indicators of serum ferritin in women in the Moscow agglomeration (2023–2024)
- 1 January 2024
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 12 (3)
Open AccessThe "Ferritin 2023" program to study population indicators of serum ferritin in women in the Moscow agglomeration (2023–2024)
- Open Access
- 22 September 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (7-8) , 387-394
New possibilities of pathogenetic correction of anemia in chronic heart failure
If chronic heart failure (CHF) is accompanied by anemic syndrome and iron defi ciency (ID) tolerance to treatment develops, the eff ectiveness of drugs that form the basis of CHF treatment decreases, and the prognosis worsens. Aim. To evaluate the possibilities of using iron preparations with hepcidin-independent absorption mechanism depending on the characteristics of iron metabolism, erythropoiesis and the level of infl ammation in patients with CHF and anemia. Material and methods. The study included 68 patients diagnosed with CHF to describe the characteristics of anemia (General group). Further, 56 patients who signed consent to the study were divided into two groups: 30 patients (Treatment Group) with standard CHF therapy and iron preparations, and 26 (Comparison Group) with standard CHF therapy only. Sucrosomial iron (SI) was used 60 mg per day orally for three months. Results. Variants of anemia in CHF: absolute ID (AID) — 43%, functional ID (FID) — 19%, anemia without ID — 38%. In the treatment group, an increase in hemoglobin (Hb, p < 0.002), hematocrit (Ht, p < 0.001), mean corpuscular volume (MCV, p < 0.002) and serum ferritin (SF, p < 0.05), in the Сomparison group only Ht, p < 0.01, and the greatest increase in Hb was detected in patients with SF < 30 μmol/l (p < 0.002). Conclusion. Anemia in CHF corresponds to the signs of anemia of chronic disease (ACD) with J, while J was detected in 62% of patients. The use of SI signifi cantly increases erythrocyte counts and SF/
- 22 September 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (7-8) , 387-394
Open AccessNew possibilities of pathogenetic correction of anemia in chronic heart failure
If chronic heart failure (CHF) is accompanied by anemic syndrome and iron defi ciency (ID) tolerance to treatment develops, the eff ectiveness of drugs that form the basis of CHF treatment decreases, and the prognosis worsens. Aim. To evaluate the possibilities of using iron preparations with hepcidin-independent absorption mechanism depending on the characteristics of iron metabolism, erythropoiesis and the level of infl ammation in patients with CHF and anemia. Material and methods. The study included 68 patients diagnosed with CHF to describe the characteristics of anemia (General group). Further, 56 patients who signed consent to the study were divided into two groups: 30 patients (Treatment Group) with standard CHF therapy and iron preparations, and 26 (Comparison Group) with standard CHF therapy only. Sucrosomial iron (SI) was used 60 mg per day orally for three months. Results. Variants of anemia in CHF: absolute ID (AID) — 43%, functional ID (FID) — 19%, anemia without ID — 38%. In the treatment group, an increase in hemoglobin (Hb, p < 0.002), hematocrit (Ht, p < 0.001), mean corpuscular volume (MCV, p < 0.002) and serum ferritin (SF, p < 0.05), in the Сomparison group only Ht, p < 0.01, and the greatest increase in Hb was detected in patients with SF < 30 μmol/l (p < 0.002). Conclusion. Anemia in CHF corresponds to the signs of anemia of chronic disease (ACD) with J, while J was detected in 62% of patients. The use of SI signifi cantly increases erythrocyte counts and SF/
- 21 July 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (6) , 308-314
Epidemiology of iron deficiency in Russia: serum ferritin values depending on sex and age
The high prevalence of iron deficiency (ID) in women and its important negative impact on the health care system is beyond doubt. The presence of severe problems of a systemic nature requires the development of special state programs to combat ID. The development of such programs is impossible without conducting epidemiological studies in each specific country. The purpose of this work is to determine the frequency and severity of ID in terms of serum ferritin (SF) in primary outpatients, depending on gender and age. The study was conducted in 15 large cities of Russia, in total, 1737 primary patients were included, of which 97 were males and 1640 were females. When studying the parameters of SF in general groups, its values are significantly lower in females, and average 40 ± 99 μg/l, while 61% of this cohort of patients have SF less than 30 μg/l, and 70% live in conditions of SF below target values, which requires the development of preventive programs to combat ID among female patients. Between the ages of 16 and 49, almost all females live in conditions of absolute ID, and it is probably in this group that the above activities should be carried out. On the contrary, as regards male patients, judging by the data obtained, a mandatory determination of SF is required to make a decision on conducting ferrotherapy.
- 21 July 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (6) , 308-314
Epidemiology of iron deficiency in Russia: serum ferritin values depending on sex and age
The high prevalence of iron deficiency (ID) in women and its important negative impact on the health care system is beyond doubt. The presence of severe problems of a systemic nature requires the development of special state programs to combat ID. The development of such programs is impossible without conducting epidemiological studies in each specific country. The purpose of this work is to determine the frequency and severity of ID in terms of serum ferritin (SF) in primary outpatients, depending on gender and age. The study was conducted in 15 large cities of Russia, in total, 1737 primary patients were included, of which 97 were males and 1640 were females. When studying the parameters of SF in general groups, its values are significantly lower in females, and average 40 ± 99 μg/l, while 61% of this cohort of patients have SF less than 30 μg/l, and 70% live in conditions of SF below target values, which requires the development of preventive programs to combat ID among female patients. Between the ages of 16 and 49, almost all females live in conditions of absolute ID, and it is probably in this group that the above activities should be carried out. On the contrary, as regards male patients, judging by the data obtained, a mandatory determination of SF is required to make a decision on conducting ferrotherapy.
- Open Access
- 6 January 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (1) , 3332
Characteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation
Aim. To determine the characteristics of erythrocyte parameters, iron metabolism, erythropoiesis, inflammation markers in patients with heart failure (CHF) and anemia.Material and methods. The study included 68 patients with HF to describe the characteristics of anemia (general group). Patients of the general group were divided into 3 subgroups depending on the serum ferritin (SF) and transferrin saturation (TS).Results. Anemia in HF is not always associated with iron deficiency (ID), characterized by inadequate production of erythropoietin, increased levels of C-reactive protein and hepcidin. From the general group of patients, the following were distinguished: absolute ID (43%), functional ID (19%), and non-ID anemia (38%).Conclusion. In the general group of patients with HF, anemia is normochromic, normocytic, characterized by high levels of C-reactive protein, hepcidin, and inadequate production of erythropoietin. Patients with absolute and functional ID do not differ in the main iron metabolism parameters and in general account for 62% (p=0,01). In these two subgroups, iron supplements should be prescribed at further stages.
- 6 January 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (1) , 3332
Open AccessCharacteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation
Aim. To determine the characteristics of erythrocyte parameters, iron metabolism, erythropoiesis, inflammation markers in patients with heart failure (CHF) and anemia.Material and methods. The study included 68 patients with HF to describe the characteristics of anemia (general group). Patients of the general group were divided into 3 subgroups depending on the serum ferritin (SF) and transferrin saturation (TS).Results. Anemia in HF is not always associated with iron deficiency (ID), characterized by inadequate production of erythropoietin, increased levels of C-reactive protein and hepcidin. From the general group of patients, the following were distinguished: absolute ID (43%), functional ID (19%), and non-ID anemia (38%).Conclusion. In the general group of patients with HF, anemia is normochromic, normocytic, characterized by high levels of C-reactive protein, hepcidin, and inadequate production of erythropoietin. Patients with absolute and functional ID do not differ in the main iron metabolism parameters and in general account for 62% (p=0,01). In these two subgroups, iron supplements should be prescribed at further stages.